Distinction of the GABA 2.29 Ppm Resonance Using Triple Refocusing at 3 T in Vivo.

Vivek Tiwari,Zhongxu An,Yiming Wang,Changho Choi

DOI: https://doi.org/10.1002/mrm.27142

2018-01-01

Magnetic Resonance in Medicine

Abstract:PurposeTo develop 1H MR spectroscopy that provides distinction of γ‐aminobutyric acid (GABA) signal at 3 T in vivo.MethodsTriple‐refocusing was tailored at 3 T, with numerical simulations and phantom validation, for distinction of the GABA 2.29‐ppm resonance from the neighboring glutamate resonance. The optimization was performed on the inter‐RF pulse time delays and the duration and carrier frequency of a non‐slice‐selective RF pulse. The optimized triple refocusing was tested in multiple regions in 6 healthy subjects, including hippocampus. The in vivo spectra were analyzed with the LCModel using in‐house basis spectra. After normalization of the metabolite signal estimates to water, the metabolite concentrations were quantified with reference to medial‐occipital creatine at 8 mM.ResultsA triple‐refocusing scheme with optimized inter‐RF pulse time delays (TE = 74 ms) was obtained for GABA detection. With optimized duration (14 ms) and carrier frequency (4.5 ppm) of the non‐slice‐selective RF pulse, the triple refocusing gave rise to distinction between the GABA 2.29‐ppm and glutamate 2.35‐ppm signals. The GABA 2.29‐ppm signal was clearly discernible in spectra in vivo (voxel size 4 to 12 mL; scan times 4.3 to 17 minutes). With a total of 24 spectra from 6 gray or white matter–dominant regions, the GABA concentration was measured to be 0.62 to 1.15 mM (Cramer‐Rao lower bound of 8 to 14%), and the glutamate level 5.8 to 11.2 mM (Cramer‐Rao lower bound of 3 to 6%).ConclusionThe optimized triple refocusing provided distinction between GABA and glutamate signals and permitted direct codetection of these metabolites in the human brain at 3 T in vivo.